Professor, Medicine - Oncology, Stanford University Medical Center
Hematology
Dr. Beverly S. Mitchell, MD
|
|
Give Review
Doctor Beverly S. Mitchell, MD works in the field of Hematology. She researched medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care She received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Elected Member" and "Whos Who in Medicine and Healthcare". Doctor Beverly S. Mitchell, MD is a published physician as well. She has 34 publications published. The latest was: Regulation of ribosomal RNA synthesis in T Cells: requirement for GTP and Ebp1. Beverly Mitchell accepts all Medicare patients.
Publications
- How do differences in treatment impact racial and ethnic disparities in Acute myeloid leukemia?
- Regulation of ribosomal RNA synthesis in T Cells: requirement for GTP and Ebp1.
- Regulation of Ribosomal Gene Expression in Cancer.
- Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.
- Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA.
- Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated Acute myeloid leukemia.
- Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with Myelodysplastic syndromes.
- Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53.
- Reactive oxygen species regulate nucleostemin oligomerization and protein degradation.
- Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.
- Synthesis of 2'-Deoxy-2'-[(18)F]Fluoro-9-β-D: -Arabinofuranosylguanine: a Novel Agent for Imaging T-Cell Activation with PET.
- Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin.
- Guanine nucleotide depletion mediates translocation of nucleolar proteins, including RNA helicase A (DHX-9).
- Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage Acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Grou...
- Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP.
- Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
- Regulation of equilibrative nucleoside uptake by protein kinase inhibitors.
- Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer.
- Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase.
- Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice.
- The proteasome--an emerging therapeutic target in cancer.
- Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion.
- Inhibition of nucleoside transport by protein kinase inhibitors.
- Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
- Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous Leukemia.
- A77 1726 induces differentiation of human myeloid Leukemia K562 cells by depletion of intracellular CTP pools.
- Inhibition of nucleoside transport by p38 MAPK inhibitors.
- Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes.
- Association of DNA polymerase mu (pol mu) with Ku and ligase IV: role for pol mu in end-joining double-strand break repair.
- Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
- Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in Acute myeloid leukemia cells.
Schools
Harvard Medical School
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Leukocytosis
- Lymphocytosis
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
University of Michigan Hospitals and Health Centers -
University of Washington -
Harborview Medical Center -
Harvard Medical School
Hospital
-
Stanford Health Care
Helpful Reviews
Similar Doctors
|
|
Dr. Rondeep S. Brar, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence L. Leung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory Heestand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel W. Neal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Leibowitz, MD |
|
|
Dr. Tamara J. Dunn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Miller, MD |
|
|
Dr. Mehrdad Mobasher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saul A. Rosenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley L. Schrier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason Gotlib, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Sandhya Srinivas, MB
This Doctor is OpenDoctor Recommended.
|